Immunotherapy combo shows promise in hodgkin lymphoma trial

NCT ID NCT07234487

Recruiting now Disease control Sponsor: St. Petersburg State Pavlov Medical University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compares two first-line treatments for advanced Hodgkin lymphoma. One group gets a new combination of the immunotherapy drug nivolumab plus chemotherapy (AVD), while the other group receives standard chemotherapy (BEACOPP-like). The goal is to see which approach is safer and more effective. About 178 adults aged 18-60 with newly diagnosed stage IIB, III, or IV Hodgkin lymphoma will take part.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CLASSICAL HODGKIN LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

classic Hodgkin lymphoma Hodgkins lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HODGKIN LYMPHOMA

Contacts and locations

Locations

A.N.Bakulev Center for cardiovascular surgery of the Russian Ministry of Health
RECRUITING

Moscow, Russia
National Medical and Surgical Center named after N.I. Pirogov
RECRUITING

Moscow, Russia
St. Petersburg State Pavlov Medical University
RECRUITING

Saint Petersburg, Russia

More trials for these conditions

Other studies related to the condition(s) this trial covers.